文献速递心力衰竭与心肌病

β受体阻滞剂撤药与射血分数保留心衰患者功能容量改善

β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction.
PubMed 文献 · JAMA Cardiol · 2024-01-01

该研究为PRESERVE-HR随机交叉试验的事后分析,纳入52例接受β受体阻滞剂治疗且存在变时性功能不全的稳定性HFpEF患者,随机撤药或继续治疗2周后交叉。撤药后峰值心率中位增加30 bpm(95%CI 25-35,P<.001),且撤药与峰值摄氧量百分比的变化关联随iLVESV连续变化而不同(交互P=.02),iLVESV较低者短期功能容量改善更明显。

要点

  • HFpEF合并变时性功能不全者,撤停β受体阻滞剂2周可显著提高峰值心率。
  • iLVESV较低的患者撤药后峰值摄氧量百分比短期改善更明显。
  • 该发现支持以iLVESV识别可能从撤药中获益的HFpEF患者。

核心结论

  • 在接受β受体阻滞剂治疗的HFpEF合并变时性功能不全患者中,较低的iLVESV可能识别出撤药后短期最大功能容量改善更明显者。

研究设计与样本

  • 基于研究者盲法、多中心、随机交叉临床试验PRESERVE-HR的事后分析,纳入52例NYHA II-III级稳定性HFpEF且接受β受体阻滞剂并存在变时性功能不全的患者。
  • 患者随机接受撤药或继续β受体阻滞剂治疗2周后交叉至相反干预。

主要发现

  • 撤停β受体阻滞剂后峰值心率中位增加30 bpm(95%CI 25-35;P<.001)。
  • β受体阻滞剂撤药与峰值摄氧量百分比变化的关联随iLVESV连续变化而不同(交互P=.02),iLVESV较低者获益更大。

临床怎么用

  • 对HFpEF合并变时性功能不全且正在使用β受体阻滞剂的患者,可考虑评估iLVESV以识别撤药后短期功能容量可能改善者。

局限性

  • 本研究为PRESERVE-HR试验的事后分析,样本量52例,仅评估2周短期效应。
  • 原文指出需进一步研究以深入调查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Increasing the patient's heart rate (HR) has emerged as a therapeutic option in patients with heart failure with preserved ejection fraction (HFpEF). However, the evidence is conflicting, and the profile of patients who benefit most from this strategy remains unclear. OBJECTIVE: To assess the association of β-blocker treatment withdrawal with changes in the percentage of predicted peak oxygen consumption (VO2) across indexed left ventricular diastolic (iLVEDV) and indexed left ventricular systolic volumes (iLVESV), and left ventricular ejection fraction (LVEF) in patients with HFpEF and chronotropic incompetence. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis was conducted using data from the investigator-blinded multicenter, randomized, and crossover clinical trial, PRESERVE-HR, that took place from October 1, 2018, through December 31, 2020, to investigate the short-term effects (2 weeks) of β-blocker withdrawal on peak oxygen consumption (peak VO2). Patients with stable HFpEF (New York Heart Association functional class II to III) receiving treatment with β-blocker and chronotropic incompetence were included. INTERVENTION: Participants in the PRESERVE-HR trial were randomized to withdraw vs continue with β-blocker treatment. After 2 weeks, they were crossed over to receive the opposite intervention. This crossover randomized clinical trial examined the short-term effect of β-blocker withdrawal on peak VO2. MAIN OUTCOMES AND MEASURES: The primary outcome was to evaluate the association between β-blocker withdrawal and short-term changes in percentage of peak VO2 across iLVEDV, iLVESV, and LVEF in patients with HFpEF and chronotropic incompetence treated with β-blocker. RESULTS: A total of 52 patients (mean age, 73 [SD, 13] years; 60% female) were randomized. The mean resting HR, peak HR, peak VO2, and percentage of peak VO2 were 65 (SD, 9) beats per minute (bpm), 97 (SD, 15) bpm, 12.4 (SD, 2.9) mL/kg per minute, and 72.4% (SD, 17.7%), respectively. The medians (minimum-maximum) of iLVEDV, iLVESV, and LVEF were 44 mL/m2 (IQR, 19-82), 15 mL/m2 (IQR, 7-32), and 64% (IQR, 52%-78%), respectively. After stopping β-blocker treatment, the median increase in peak HR was plus 30 bpm (95% CI, 25-35; P < .001). β-Blocker cessation was differentially associated with change of percentage of peak VO2 across the continuum of iLVESV (P for interaction = .02), indicating a greater benefit in those with lower iLVESV. CONCLUSIONS AND RELEVANCE: In this study, results showed that in patients with HFpEF and chronotropic incompetence receiving treatment with β-blocker, lower iLVESV may identify those with a greater short-term improvement in maximal functional capacity after stopping β-blocker treatment. Further studies are warranted for further investigation. TRIAL REGISTRATION: ClinicalTrials.gov (NCT03871803).

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Palau, de la Espriella, Seller, et al. β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2024. PMID: 38324280. doi:10.1001/jamacardio.2023.5500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。